The Role of Neuropeptide Y in the Expression and Extinction of Fear-Potentiated Startle

doi:10.1523/JNEUROSCI.2305-08.2008

J Neurosci. Author manuscript; available in PMC 2009 May 26.

Published in final edited form as:

J Neurosci. 2008 November 26; 28(48): 12682–12690.

doi: 10.1523/JNEUROSCI.2305-08.2008

PMCID: PMC2621075

NIHMSID: NIHMS81726

The Role of Neuropeptide Y in the Expression and Extinction of Fear-Potentiated Startle

Alisa R. Gutman, Yong Yang, Kerry J. Ressler, and Michael Davis

Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine and Center for Behavioral Neuroscience, Atlanta, GA

Corresponding Author: Michael Davis, PhD, Robert W. Woodruff Professor, Department of Psychiatry and Behavioral Sciences, Center for Behavioral Neuroscience, Yerkes Research Center, Emory University, 954 Gatewood Dr, Atlanta, GA 30329, USA, 404-727-3591

The publisher's final edited version of this article is available free at J Neurosci

See other articles in PMC that cite the published article.

Abstract

Neuropeptides are a promising target for novel treatments for anxiety and other psychiatric disorders and neuropeptide Y (NPY) has emerged as a key component of anxiolytic circuits in the brain. For this reason, we have evaluated the role of NPY in the expression and extinction of conditioned fear. We found that intracerebroventricular (i.c.v.) administration of NPY inhibits both baseline acoustic startle and the expression of fear-potentiated startle. Infusion of NPY (10 pmol/side) into the basolateral, but not the medial, nucleus of the amygdala reproduced the i.c.v. effect. Central administration of NPY (10 μg) also enhanced within-session extinction of fear-potentiated startle. This finding, coupled with the growing body of literature correlating NPY with resilience in humans, led us to the hypothesis that NPY may enhance the extinction of conditioned fear. When NPY (10 μg) is administered i.c.v. prior to extinction training, extinction retention for both the contextual and cued components of conditioned fear is enhanced when tested 48 hours later off drug. Additionally, we found that intra-basolateral amygdala administration of the NPY Y₁ receptor antagonist BIBO 3304 (200 pmol/side) prior to extinction training led to a profound deficit in extinction retention. This is the first evidence that NPY facilitates and an NPY antagonist blocks the extinction of conditioned fear. We believe that the role of NPY in the extinction of conditioned fear may, at least in part, explain the mechanism underlying the association between NPY and psychobiological resilience in humans.

Keywords: Neuropeptide, Extinction, Fear, Startle, Rat, basolateral Amygdala, Amygdala, Behavior

Introduction

While traditional psychiatry research has focused on understanding ‘what goes wrong’ in individuals with psychiatric disease, other studies have tried to analyze ‘what goes right’ in individuals who do not develop psychopathology even when exposed to trauma and other risk factors for illness. More precisely, the importance of identifying resilience factors in addition to vulnerability factors is being recognized. Neuropeptide Y (NPY) has emerged as a potentially important component of resiliency systems in the brain.

While a few studies support a role for NPY in learning (Flood et al., 1989; Nakajima et al., 1994; Redrobe et al., 2004), most involve its role in stress and anxiety. Changes in NPY fiber staining and mRNA expression are observed in the hippocampus and amygdala following both acute and chronic restraint stress, (Thorsell et al., 1998; Thorsell et al., 1999; Conrad and McEwen, 2000; Teppen, 2003) and overexpression of NPY attenuates behavioral responses to stress (Thorsell et al., 2000; Primeaux et al., 2005).

Intracerebroventricular or intra-amygdala infusion of NPY leads to an anxiolytic behavioral profile in several animal models (Flood et al., 1989; Heilig et al., 1992; Broqua et al., 1995; Heilig, 1995; Britton et al., 1997; Sajdyk et al., 1999; Kokare et al., 2005). NPY colocalizes with GABA in local circuit neurons of the basolateral amygdala (BLA) (McDonald and Pearson, 1989) and likely exerts inhibitory control on BLA projection neurons. The anxiolytic effects of NPY generally involve the Y₁ receptor (Heilig, 1995; Wieland et al., 1995; Kask et al., 1999; Sajdyk et al., 1999; Primeaux et al., 2005), although Y₂ and Y₅ receptors have also been implicated (Sajdyk et al., 2002a; Sajdyk et al., 2002b). Most germane to the question of resilience, Sajdyk et al. found that injections of NPY into the BLA blocked the anxiogenic effects of a chemical or physical stressor, an effect that persisted for 8 weeks after a series of NPY infusions into the BLA (Sajdyk et al., 2008). Furthermore, NPY fiber staining in the hippocampus and amygdala is increased when rats are exposed to a fearful context (Teppen, 2003), and in the BLA when exposed to a cue (Gutman, Ressler, and Davis, unpublished observations). Taken together these results led us to ask the mechanistic question, ‘How could increased levels of NPY be protective?’

We hypothesized that NPY-induced resilience may result because it enhances extinction of conditioned fear. To test this, we first needed to characterize the effects of NPY on cued fear conditioning and then determine whether NPY might modulate extinction learning.

Materials and Methods

Animals

The procedures used were approved by the Institutional Animal Care and Use Committee of Emory University and in compliance with National Institutes of Health (NIH) guidelines for the care and use of laboratory animals. Adult male Sprague-Dawley rats (Charles River, Raleigh, NC) weighing between 350 and 500 grams were used. Animals were housed in groups of four in a temperature-controlled (24°C) animal colony, with ad libitum access to food and water. They were maintained on a 12 hr light/dark cycle with lights on at 8:00 A.M, with all behavioral procedures performed during the rats’ light cycle.

Surgery

For studies employing intracerebroventricular (i.c.v.) drug administration, 22-gauge stainless-steel guide cannulae (Plastics One, Roanoke, VA) were implanted under ketamine/xylazine anesthesia, and secured using dental cement and 1/8″ cap screws (coordinates: AP:0, ML: −1.6, DV: −5.0; nosebar: +5.0). Animals were allowed 7–10 days recovery before habituation to the testing context and subsequent behavioral testing. Similar procedures were used to implant bilateral cannulae aimed at the basolateral complex of the amygdala (22-gauge guide cannulae, AP: −3.1, ML: +/− 5.4, DV: −8.4 from bregma; nosebar: −3.6) and medial nucleus of the amygdala (MeA) (22-gauge guide cannulae, AP: −2.76, ML: +/− 3.5, DV: −8.5 from dura). We used the medial amygdala as a control for regional specificity, because it also expresses NPY receptors and peptide (Chronwall et al., 1985; Parker and Herzog, 1999; Kopp et al., 2002). Following behavioral testing, cannulated animals were sacrificed and cannula placement was assessed on cryostat-sectioned tissue. Animals with both cannula correctly placed either i.c.v. or within the amygdala were included for analysis.

Startle Apparatus

Animals were trained and tested in 8 × 15 × 15 cm Plexiglas and wire-mesh cages, with floors consisting of four 6.0-mm-diameter stainless-steel bars spaced 18 mm apart. Each cage was suspended between compression springs within a steel frame and located within a custom-designed 90 × 70 × 70 cm ventilated sound-attenuating chamber. Background noise (60-dB wide-band) was provided by a General Radio Type 1390-B noise generator (Concord, MA) and delivered through high-frequency speakers (Radio Shack Supertweeter; Tandy, Fort Worth, TX) located 5 cm from the front of each cage. Sound level measurements (sound pressure level) were made with a Bruel & Kjaer (Marlborough, MA) model 2235 sound-level meter (A scale; random input) with the microphone (Type 4176) located 7 cm from the center of the speaker (approximating the distance of the rat’s ear from the speaker). Startle responses were evoked by 50-msec, 95-dB white-noise bursts generated by a Macintosh G3 computer soundfile (0–22 kHz), amplified by a Radio Shack amplifier (100 W; model MPA-200; Tandy), and delivered through the same speakers used to provide background noise. An accelerometer (model U321AO2; PCB Piezotronics, Depew, NY) affixed to the bottom of each cage produced a voltage output proportional to the velocity of cage movement. This output was amplified (model 483B21; PCB Piezotronics) and digitized on a scale of 0–2500 U by an InstruNET device (model 100B; GW Instruments, Somerville, MA) interfaced to a Macintosh G3 computer. Startle amplitude was defined as the maximal peak-to-peak voltage that occurred during the first 200 msec after onset of the startle-eliciting stimulus. The CS was a 3.7-sec light (82 lux) produced by an 8 W fluorescent bulb (100 msec rise time) located 10 cm behind each cage. Luminosity was measured using a VWR light meter (Atlanta, GA). The US was a 0.5-sec shock, delivered to the floorbars and produced by a shock generator (SGS-004; Lehigh Valley, Beltsville, MD). Shock intensities (measured as in Cassella et al., 1986) were 0.4 mA. The presentation and sequencing of all stimuli were under the control of the Macintosh G3 computer using custom-designed software (The Experimenter; Glassbeads Inc., Newton, CT).

Drugs

NPY (Bachem Biosciences, King of Prussia, Pennsylvania) and (R)-N-[[4-aminocarbonylaminomethyl)-phenyl]methyl]-N²-(diphenylacetyl)-argininamide trifluoroacetate (BIBO 3304, given as a generous gift from Dr. Marcus Schindler, Boehringer-Ingelheim, Biberach, Germany) were suspended in artificial cerebrospinal fluid with 1% bovine serum albumin. BIBO 3304 is a highly selective antagonist for the Y₁ receptor with subnanomolar affinity for both the human and rat receptors (IC₅₀ values 0.38 ± 0.06 nM and 0.72 ± 0.42 nM, respectively) and shows minimal activity in more than 75 different receptor binding and enzyme systems, including 1,000–10,000 fold lower affinity for the NPY Y₂, Y₄, and Y₅ receptors (IC₅₀ values > 1000 nM) (Wieland et al., 1998). Some studies have used the inactive (S-) enantiomer, BIBO 3457, as a control for nonspecific effects of drug. However, since our study includes both agonist and antagonist experiments that yield complementary results, we felt that a vehicle control was sufficient. All infusions were given through microinjection cannulae (28-gauge) connected with PE-20 tubing to a 10 μl Hamilton syringe. I.c.v. infusions were administered at a flow rate of 10 μl/min with a total injection volume of 5 μl. Intra-amygdala infusions were administered at a flow rate of 0.25 μl/min with a total injection volume of 0.5 μl/side. Microinjection cannulae were left in place for 2–5 min (intra-BLA and i.c.v., respectively) to allow for diffusion away from cannulae to prevent backflow.

Baseline Startle Testing

Animals were placed in the startle chambers for 20 min on each of 2 days prior to training to habituate them to the test procedures and chambers and to minimize the effects of contextual conditioning. Baseline startle testing consisted of a 5-min habituation period followed by 30 startle stimuli (50-msec, 95-dB white-noise burst).

Fear Conditioning

On 2 consecutive days following baseline testing, rats were returned to the same chambers and presented with 10 pairings of a light (3.7 sec) coterminating with a 0.4-mA, 0.5-sec shock (4-min variable inter-trial interval).

Matching for fear-potentiated startle levels

Twenty-four hours following the last fear-conditioning session, animals were returned to the same chambers and presented with startle stimuli (50-msec, 95-dB white-noise bursts) in the presence or absence of the light conditioned stimulus [5 light-noise compounds (LN) and 5 noise-alone trials (NA)]. Increased startle in the presence of the light-CS was taken as a measure of conditioned fear, and the magnitude of the fear response was calculated as the percentage by which startle increased when elicited in the presence of light-CS versus when it was omitted [% fear-potentiated startle, [(LN−NA)/NA)*100]. Using these measurements, animals were divided into groups displaying equivalent levels of fear-potentiated startle prior to testing with NPY.

Behavioral Procedures, Experiment 1, The effect of central NPY on baseline startle

Animals (n = 16) were tested for effects of NPY on baseline startle using a within-subjects repeated measures design in which each animal received an i.c.v. infusion of 0, 1, 3, or 10 μg NPY on each of four days in a counterbalanced fashion. Drug was infused 60 min prior to baseline startle testing and statistics among the four drug groups were analyzed using a One-Way Repeated Measures ANOVA.

Behavioral Procedures, Experiment 2, The effect of central NPY on the expression of fear-potentiated startle

To evaluate levels of expression of fear-potentiated startle, animals were returned to the chamber and presented with a 46-min test similar to that described for matching, but consisting of a 5-min acclimation period followed by 30 LN and 30 NA trials. Animals (n=11) were infused i.c.v. with 10 μg NPY or vehicle 60 min prior to testing. Interval between infusion and testing and drug dose were based on previous studies (Heilig et al., 1989; Broqua et al., 1995). A within-subjects crossover design was employed in which half the rats were infused with NPY on Day 1 and vehicle on Day 2 and the other half administered drugs in the opposite pattern with 48 hrs between Day 1 and Day 2. The data were analyzed using a paired t-test.

Behavioral Procedures, Experiment 3, The effect of amygdala administration of NPY on the expression of fear-potentiated startle

To evaluate levels of expression of fear-potentiated startle, animals were returned to the chamber and presented with a 46-min test consisting of a 5-min acclimation period followed by 30 LN and 30 NA trials. We used a within-subjects crossover design, and animals were given 1 day of retraining before their second expression test to reduce the probability that extinction during the Day 1 test session would influence the Day 2 test data. The magnitude of fear-potentiated startle was calculated as for matching above. Animals were infused bilaterally immediately prior to the expression test with vehicle or 10 pmol NPY/side into either the basolateral (n = 13) or medial amygdala (n = 10). This dose has been used previously and has consistently shown behavioral effects in anxiety paradigms (Sajdyk et al., 1999). Values for percent fear-potentiated startle were grouped into blocks of 5 trials each and statistics were performed using a Two-Way Repeated Measures ANOVA with block (1–5) and treatment (vehicle, NPY) as factors.

Behavioral Procedures, Experiment 4, The effect of amygdala administration of an NPY Y1 receptor antagonist on the expression of fear-potentiated startle

For Experiment 4, animals were infused bilaterally with vehicle (n = 20) or 200 pmol/side BIBO 3304 into either the BLA (n = 15) or medial (n = 7) amygdala immediately prior to an expression test consisting of a 5-min acclimation period followed by 30 LN and 30 NA trials. Comparisons between groups were performed using Two-Way Repeated Measures ANOVA. The intra-amygdala dose of BIBO 3304 was chosen from previous studies in an anxiety paradigm (Sajdyk et al., 1999; Wieronska et al., 2004).

Behavioral Procedures, Extinction Studies

Because we had found previously that NPY significantly decreased baseline startle, which can cause interpretive problems when evaluating extinction data, all extinction tests were performed 48 hours after NPY infusion. Results from Experiments 1 and 2 indicated that this was long enough for the drug to no longer affect baseline startle or expression of startle and we could thereby measure extinction retention without concerns of lingering drug effects. An exception was when determining the effects of NPY on within-session extinction, wherein the drug had to be given right before testing to measure its effects on extinction.

Pre-Extinction Test

Twenty-four hours following the last fear-conditioning session, animals were returned to the same chambers and given a short test to evaluate fear-potentiated startle (5 CS alone and 5 light-CS test trials). Using these measurements, animals were divided into groups displaying equivalent levels of fear-potentiated startle prior to extinction training.

Behavioral Procedures, Experiment 5, Effect of i.c.v. NPY on within-session extinction

Animals were returned to the chamber and presented with a 46-min test consisting of a 5-min acclimation period followed by 30 LN and 30 NA trials to evaluate levels of within-session extinction. Animals (n=11) were infused i.c.v. with 10 μg NPY or vehicle 60 min prior to testing. Interval between infusion and testing and drug dose were based on previous studies (Heilig et al., 1989; Broqua et al., 1995). A within-subjects crossover design was employed and the drug was allowed to wash out for 48 hrs before testing with the other condition. Data were analyzed using a Two-Way Repeated Measures ANOVA with block (5 trials/block, blocks 1–6) and treatment (vehicle, NPY) as factors.

Behavioral Procedures, Experiment 6, Effect of i.c.v. NPY on extinction retention

Five days following the last fear conditioning session, animals were administered 10 mg NPY (n = 10) or vehicle (n = 10) i.c.v. 30 min prior to the presentation of 30 light-CSs (light-alone, LA) in the absence of footshock (3.7-sec light, 30-sec intertrial interval). Relative level of extinction retention was evaluated 48 hrs later with a retention test (15 LN and 15 NA). Fear-potentiated startle was calculated as it was for the pre-extinction test and data were analyzed using an unpaired t-test to compare percent fear-potentiated startle and Two-Way Repeated Measures ANOVA to compare NA values in the baseline startle, pre-extinction, and post-extinction tests.

Behavioral Procedures, Experiment 7, Effect of i.c.v. NPY on extinction retention with context shift

Because Experiment 2 showed that NPY facilitated extinction of context conditioning, which made it difficult to evaluate its effects on cued conditioning, animals in this study were fear conditioned in one context (A), as previously described, but then given extinction training in another context (B). Context B consisted of the following elements: 1) sandpaper inserts placed over the floorbars, 2) 4 chains hanging down from the top of the cage, 3) Velcro inserts placed over the side walls, 4) cotton soaked in 100% ethanol below the cage inside of the chamber. Five days following the last fear conditioning session, animals were placed into Context B and administered 10 μg NPY (n = 7) or vehicle (n = 7) i.c.v. 30 min prior to the presentation of 30 LA. Relative level of extinction retention was evaluated 48 hours later in Context B with a retention test (15 LN and 15 NA). Due to often large amounts of within-session extinction during extinction retention tests, we found that data from the first block of the extinction retention test best exemplifies levels of between-session extinction. Fear-potentiated startle was calculated as for the pre-extinction test and data were analyzed using unpaired t-test to compare block 1 for the vehicle and NPY groups and paired t-test to compare pre-extinction and post-extinction values for each group.

Behavioral Procedures, Experiment 8, Effect of BIBO 3304 in the amygdala on extinction retention

Five days following the last fear conditioning session, animals were infused bilaterally with vehicle (n = 20) or 200 pmol/side BIBO 3304 into either the BLA (n = 15) or medial amygdala (n = 7) immediately prior to extinction training consisting of 30 LN and 30 NA stimuli in the absence of footshock (30-sec intertrial interval). Animals were then tested 48 hours later with a test (15 LN, 15 NA) to evaluate levels of extinction retention. The intra-amygdala dose of BIBO 3304 used was chosen from previous studies in an anxiety paradigm (Sajdyk et al., 1999; Wieronska et al., 2004). In contrast to previous experiments, in this extinction training session startle stimuli were given 3.2 sec after each light (i.e. a LN trial) to evaluate the effects of drug on the expression and extinction of fear-potentiated startle in the same group of animals. A prior parametric study comparing the difference between extinction training with light-alone trials and light-noise trials indicated that both paradigms yield similar levels of extinction. It should be noted that we did not observe a difference in noise-alone values between groups when infusing into the amygdala in previous studies employing infusion of BIBO 3304 into the amygdala, and therefore used our standard context for this experiment. Data were analyzed using One-Way ANOVA to compare percent fear-potentiated startle in block 1 for the three groups.

Results

Experiment 1, Central NPY activation inhibits baseline startle

Before preceding with an evaluation of the effects of NPY in our learning paradigms, we generated a dose-response curve (Figure 1) for the effect of i.c.v. administration of 0,1,3, and 10 μg of NPY on baseline startle. One-Way Repeated Measures ANOVA showed that NPY administration dose-dependently decreased baseline startle amplitude, with an overall effect between treatments (p < 0.05, F_(3,61) = 4.09). Student-Newman-Keuls post-hoc analysis indicated significantly lower levels of baseline startle between 3 and 10 μg NPY and vehicle (p < 0.05) and a trend-level decrease in baseline startle between 1 μg NPY and vehicle (p = 0.08).

Figure 1

Dose-response curve showing that activation of central NPY receptors inhibits baseline startle

Experiment 2, Central NPY activation inhibits the expression of fear-potentiated startle

Administration of NPY reduced overall startle amplitude on both noise-alone and light-noise trials compared to the vehicle condition, as well as a significant reduction in the difference score (LN-NA) between conditions (Figure 2, paired t-test, p < 0.01). Importantly, NPY inhibited the expression of fear-potentiated startle, measured as a reduction in percent fear-potentiated startle (paired t-test, p < 0.05), that cannot be accounted for by its overall reduction in startle amplitude.

Figure 2

Central NPY activation inhibits the expression of fear-potentiated startle

Experiment 3, Intra-basolateral amygdala activation of NPY inhibits the expression of fear-potentiated startle

NPY infusion into the basolateral, but not the medial, nucleus of the amygdala inhibited the expression of fear-potentiated startle (Figure 3A). Two-Way Repeated Measures ANOVA for the BLA group identified a significant overall effect of time (p < 0.001, F_(5,155) = 8.704) and a time by treatment interaction (p < 0.05, F_(5,155) = 2.897). Student-Newman-Keuls post hoc analysis revealed a significant difference between NPY and vehicle for block 1 (p < 0.05). No effect was found for the medial amygdala group (Figure 3B). NPY had no effect on baseline startle responding in either region (Figure 3C), indicating that the observed effect on expression of fear-potentiated startle is not merely an effect on the startle reflex itself and that the effects of i.c.v. NPY on baseline startle was probably not due to effects on these amygdala nuclei.

Figure 3

Intra-basolateral amygdala activation of NPY inhibits the expression of fear-potentiated startle

Experiment 4, Intra-amygdala antagonism of NPY Y1 receptors has no effect on the expression of fear-potentiated startle

Two-Way Repeated Measures ANOVA indicated that infusion of the NPY Y₁ receptor antagonist BIBO3304 into the BLA or medial amygdala immediately prior to testing had no effect of on the expression of fear-potentiated startle (Figure 4A). There was no observed effect on baseline startle in either region, as measured by NA values during the expression test (Figure 4B).

Figure 4

Intra-amygdala antagonism of NPY Y1 receptors has no effect on the expression of fear-potentiated startle

Experiment 5, Central NPY activation enhances within-session extinction of fear-potentiated startle

Figure 5 demonstrates a significant enhancement of within-session extinction in the NPY condition as compared to vehicle. Two-Way Repeated Measures ANOVA indicates significant main effects for both treatment (F_(1,131) = 7.235, p < 0.05) and block (F_(5,131) = 5.444, p < 0.001), although the interaction was not significant. However, Student-Newman-Keuls post-hoc analysis indicated that fear-potentiated startle in the NPY group was significantly lower than in the vehicle condition at blocks 4 (p < 0.01) and 6 (p < 0.01).

Figure 5

Central NPY activation enhances within-session extinction of fear-potentiated startle

Experiment 6, Central NPY activation enhances extinction to the contextual component of fear-potentiated startle

We did not observe an overall effect of NPY on percent fear-potentiated startle in our extinction retention test (Figure 6B). However, we did observe an overall decrease in startle amplitude in the NPY group (Two-Way Repeated Measures ANOVA, significant main effect of treatment (F_(1,35) = 4.902, p < 0.05) and a significant reduction during noise-alone trials (Figure 6C, p < 0.05). The baseline change between the vehicle and NPY groups made a comparison between percent fear difficult to verify, and compelled us to examine this decrease in noise-alone trials further.

Figure 6

Central administration of NPY prior to extinction training decreased overall startle amplitude but not % fear-potentiated startle. (A) Animals were implanted with i.c.v. cannulae 7–10 days prior to behavioral training. 30 min prior to extinction (more ...)

In comparing noise-alone startle responses before training (Baseline), after training (Pre-Ext), and after extinction (Post-Ext), Two-Way Repeated Measures ANOVA identified a significant main effect of test session (F_(2,59) = 6.545, p < 0.01) and Student-Newman-Keuls post hoc analysis revealed an increase in startle response for both groups from Baseline to Pre-Ext (p < 0.05), indicative of contextual fear conditioning (Figure 7B). In the vehicle group, we observed no difference between our Pre-Ext and Post-Ext values; whereas, in the NPY group, there was a reduction in startle response from Pre-Ext to Post-Ext (p < 0.05) and no difference between the Baseline and Post-Ext startle amplitude. These data suggest that NPY enhanced extinction of contextual conditioning.

Figure 7

Central administration of NPY enhances the extinction to the contextual component of fear-potentiated startle

Experiment 7, Central NPY activation enhances the extinction of fear-potentiated startle in an ABB paradigm

Animals who received NPY prior to extinction training showed significantly lower fear-potentiated startle in the post-extinction test than vehicle controls (p < 0.05). Furthermore, there was significant extinction in the NPY group (p < 0.001) but not in the vehicle group, as measured by a decrease in percent fear-potentiated startle from pre-extinction to post-extinction. Interestingly, there was no longer a significant difference in baseline startle during the extinction retention test in our groups (Figure 8C), indicating that the shift in context was effective in reducing contextual conditioning, allowing NPY’s faciliatation of extinction of cued conditioning to be detected.

Figure 8

Central administration of NPY enhances the extinction of fear-potentiated startle

Experiment 8, Intra-basolateral amygdala antagonism of NPY Y1 receptors blocks the extinction of fear-potentiated startle

In comparing levels of percent fear-potentiated startle among groups receiving vehicle, BIBO 3304 into the BLA, and BIBO 3304 into the medial amygdala prior to extinction training, One-Way ANOVA identified a significant main effect of treatment (Figure 9, F_(2,40) = 3.281, p < 0.05). Student-Newman-Keuls post hoc analysis indicated that animals that received BIBO3304 into the BLA showed significantly greater fear-potentiated startle during the extinction retention test as compared to vehicle (p < 0.05). No effect was observed following BIBO 3304 infusion into the medial amygdala. Results from prior experiments indicated that BIBO 3304 had no effect on baseline startle in either region. These results indicated that blockade of Y1 receptors in the amygdala attenuated extinction.

Figure 9

Infusion of the NPY Y₁ receptor antagonist BIBO 3304 in the basolateral amygdala blocks the extinction of fear-potentiated startle

Discussion

We found that i.c.v. administration of NPY enhances the rate of within-session extinction and extinction retention for both contextual and cued aspects of conditioned fear and that antagonism of NPY Y₁ receptors in the BLA results in decreased extinction retention, suggesting that endogenous NPY is important for the development of extinction.

Additionally, we have shown that administration of exogenous NPY inhibits the expression of fear-potentiated startle. The blockade of fear-potentiated startle was observed after i.c.v. and intra-BLA, but not intra-MeA, infusion of NPY. Moreover, we observed a dose-dependent reduction in baseline startle following i.c.v. administration of NPY. However, this was not seen in the amygdala, at least at the dose that was used, indicating the effects of NPY on fear-potentiated startle were not an artifact of a change in baseline startle.

Our finding that NPY infusion into the BLA, but not the MeA, inhibits the expression of fear-potentiated startle is consistent with previous findings. NPY is able to inhibit excitatory transmission in the amygdala (Molosh and Rainnie, 2007, unpublished observations). Electrophysiological data have shown that NPY agonists inhibit glutamate release in the hippocampus (Colmers et al., 1987; Qian et al., 1997). Pharmacological studies have shown that the expression of fear-potentiated startle is dependent on AMPA glutamate receptors in the BLA (Kim et al., 1993; Walker and Davis, 1997; Walker et al., 2005). Therefore, it is likely that NPY is acting to decrease glutaminergic transmission in the BLA, thereby suppressing excitatory output from the amygdala and leading to the observed inhibition of fear-potentiated startle. We feel that the medial amygdala (MeA) is an ideal control region for these experiments, both because of its proximity to the BLA and because it expresses both NPY receptors and peptide (Chronwall et al., 1985; Parker and Herzog, 1999; Kopp et al., 2002). Some evidence suggests that the central amygdala, a region responsible for output of information from the amygdala (Davis, 2000), is also important for NPY signaling (Heilig et al., 1993; Heilig, 2004). Since the reduction in expression of fear-potentiated startle observed in the BLA was less than that seen with i.c.v. infusion, it is possible that another region helps mediate the i.c.v. effects. Future experiments can evaluate if NPY has effects in either the central amygdala or the bed nucleus of the stria terminalis, another output nucleus of the amygdala.

While we attempted to determine the receptor subtype mediating the reduction of fear-potentiated startle, our data remain inconclusive. We were not particularly surprised by the lack of effect of the Y₁ receptor antagonist BIBO 3304 on the expression of fear-potentiated startle. Other studies have found no effect of BIBO 3304 alone on baseline behavioral measures, such as social interaction (Sajdyk et al., 1999), suggesting the basal tone of NPY in the BLA may not be high enough to observe effects of an antagonist alone. This does not diminish the significance of our findings; rather, it suggests that while enhanced NPY signaling can inhibit the expression of conditioned fear, endogenous NPY is not necessary for normal expression of fear. Alternatively, it is possible that another NPY receptor subtype is involved. Y₅ receptors in the BLA are implicated in anxiety-related behaviors (Sajdyk et al., 2002a).

The finding that infusion of BIBO 3304 inhibits extinction of fear-potentiated startle suggests that the Y₁ receptor modulates regulation of extinction learning in the BLA. This supports prior pharmacologic and genetic studies demonstrating that the Y₁ receptor mediate anxiolytic effects of NPY (Kask et al., 2002; Thorsell and Heilig, 2002). Y₁ receptor agonists increase punished responding in a conflict test (Britton et al., 1997) and antisense inhibition or a Y₁ receptor antagonist blocks anxiolytic-like effects of NPY on the elevated plus-maze and social interaction (Heilig, 1995; Sajdyk et al., 1999). Bilateral administration of the nonpeptide Y₁ receptor antagonist BIBP3226 into the amygdala results in increased anxiety-related behavior in the elevated plus-maze (Primeaux et al., 2005). A recent study with NPY Y₁ receptor null mice has shown that the Y₁ receptor is necessary for anxiolytic-like effects of i.c.v. NPY on the elevated plus-maze (Karlsson et al., 2008).

Because we typically see very little context conditioning using our parameters for measuring startle, we train and test animals in the same context. However, the results in Experiment 2 indicated considerable context conditioning and suggested that NPY was facilitating its extinction, thereby masking measurement of its possible effect on cue extinction. While the enhancement of extinction to contextual fear is an important finding, we wanted to determine whether or not central administration of NPY could also enhance extinction of cued fear. For this reason, we repeated the previous experiment but altered our testing context for extinction training and post-extinction testing (Experiment 7).

We no longer saw a difference in noise-alone startle amplitude between our NPY and vehicle groups in the Post-Ext test and were therefore able to compare percent fear in our groups since we no longer had differential shifts in our baseline startle values. Figure 8 shows that the NPY group had significantly lower percent fear-potentiated startle in the extinction retention test leading to the conclusion that exogenous administration of NPY can enhance both within-session and between-session extinction of fear-potentiated startle. Enhanced retention of extinction measured by lower levels of fear-potentiated startle could conceivably be explained by a lingering effect of NPY on fear-potentiated startle at test. However, we have observed in several other experiments that effects of NPY on baseline or fear-potentiated startle are gone by 48 hours after infusion. While these studies only test at 48 hours, we anticipate that these effects will persist long after this timepoint. Future experiments evaluating spontaneous recovery with this model can further elucidate the duration of the effect.

We chose to infuse an NPY antagonist, and not NPY peptide, into the BLA because antagonist studies provide a more direct approach for evaluating how endogenous systems function. Significantly higher levels of percent fear-potentiated startle during the extinction retention test were found following infusion of BIBO 3304 into the BLA. This demonstrates that blockade of NPY interferes with normal extinction and suggests that under normal conditions endogenous NPY Y₁ receptors are activated during the extinction of conditioned fear. Remarkably, BIBO 3304 has no effect on baseline startle or expression of fear-potentiated startle when infused into the BLA (Experiment 4) thereby supporting the notion that our observed effects on extinction retention are not due to lingering effects of the drug itself but rather modulation of learning in the BLA.

Extinction of conditioned fear is dependent on NMDA glutamate receptors in the amygdala (Falls et al., 1992; Sotres-Bayon et al., 2007). GABAergic interneurons mediate inhibition of glutaminergic excitatory transmission in the basolateral amygdala (Rainnie et al., 1991). Studies evaluating the electrophysiological effects of NPY in the arcuate nucleus indicate that NPY can inhibit GABAergic transmission (Acuna-Goycolea et al., 2005). It is possible that NPY could be inhibiting a subpopulation of interneurons in the BLA, thereby disinhibiting the glutaminergic neurons responsible for extinction.

In conclusion, we believe that increases of NPY in the hippocampus when rats are exposed to a fearful context (Teppen, 2003) or in the amygdala following a fearful cue (Gutman, Ressler, and Davis, unpublished observations) reflect its involvement in extinction and that its ability to improve resilience is based, in part, on its facilitation of extinction. This might also predict that enhancement of NPY Y₁ receptor activation could be a potential adjunct for extinction-based psychotherapy, such as exposure therapy. Currently, the lack of available nonpeptide systemic NPY Y₁ receptor agonists prohibits the direct clinical testing of this approach. An alternative strategy would take advantage of the presynaptic autoreceptor function of NPY Y₂ receptors, which have been found to inhibit transmitter release (Michel et al., 1998). Administration of antagonists to the NPY Y₂ autoreceptor could lead to an endogenous enhancement of NPY Y₁ receptor activation. This autoreceptor function may explain why administration of BIIE0246, a selective NPY Y₂ receptor antagonist, has an anxiolytic-like effect in the elevated plus-maze in rats (Bacchi et al., 2006). Genetic manipulation of the Y₂ receptor further support this hypothesis, with Y₂ receptor knockout mice exhibiting reduced anxiety in the open field and elevated plus-maze (Redrobe et al., 2003; Tschenett et al., 2003). Further studies are necessary to evaluate the merit of this approach in other models. Finally, it is conceivable that the ability of NPY to facilitate extinction observed in the present study might in some way be connected to the association between resilience and enhanced levels of NPY, such as those observed in soldiers under high stress and following trauma in individuals who do not develop PTSD (Morgan et al., 2000; Yehuda et al., 2006).

Figure 10

Cannulae placements for BLA (circles) and MeA (triangles) in Experiments 3, 4, and 8.

Acknowledgments

Support was provided by NIH (MH047840), the Center for Behavioral Neuroscience (NSF agreement IBN-987675), and by an NIH/NCRR base grant (P51RR000165) to Yerkes National Primate Research Center. The authors wish to thank members of the Davis lab for their support and insightful comments.

Literature Cited

Acuna-Goycolea C, Tamamaki N, Yanagawa Y, Obata K, van den Pol AN. Mechanisms of neuropeptide Y, peptide YY, and pancreatic polypeptide inhibition of identified green fluorescent protein-expressing GABA neurons in the hypothalamic neuroendocrine arcuate nucleus. J Neurosci. 2005;25:7406–7419. [PubMed]
Bacchi F, Mathe AA, Jimenez P, Stasi L, Arban R, Gerrard P, Caberlotto L. Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze. Peptides. 2006;27:3202–3207. [PubMed]
Britton KT, Southerland S, Van Uden E, Kirby D, Rivier J, Koob G. Anxiolytic activity of NPY receptor agonists in the conflict test. Psychopharmacology (Berl) 1997;132:6–13. [PubMed]
Broqua P, Wettstein JG, Rocher MN, Gauthier-Martin B, Junien JL. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav Pharmacol. 1995;6:215–222. [PubMed]
Chronwall BM, DiMaggio DA, Massari VJ, Pickel VM, Ruggiero DA, O’Donohue TL. The anatomy of neuropeptide-Y-containing neurons in rat brain. Neuroscience. 1985;15:1159–1181. [PubMed]
Colmers WF, Lukowiak K, Pittman QJ. Presynaptic action of neuropeptide Y in area CA1 of the rat hippocampal slice. J Physiol. 1987;383:285–299. [PubMed]
Conrad CD, McEwen BS. Acute stress increases neuropeptide Y mRNA within the arcuate nucleus and hilus of the dentate gyrus. Brain Res Mol Brain Res. 2000;79:102–109. [PubMed]
Davis M. The role of the amygdala in conditioned and unconditioned fear and anxiety. In: Aggleton JP, editor. The Amygdala. New York: Oxford University Press; 2000. pp. 213–287.
Flood JF, Baker ML, Hernandez EN, Morley JE. Modulation of memory processing by neuropeptide Y varies with brain injection site. Brain Res. 1989;503:73–82. [PubMed]
Heilig M. Antisense inhibition of neuropeptide Y (NPY)-Y1 receptor expression blocks the anxiolytic-like action of NPY in amygdala and paradoxically increases feeding. Regul Pept. 1995;59:201–205. [PubMed]
Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides. 2004;38:213–224. [PubMed]
Heilig M, Soderpalm B, Engel JA, Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl) 1989;98:524–529. [PubMed]
Heilig M, McLeod S, Koob GK, Britton KT. Anxiolytic-like effect of neuropeptide Y (NPY), but not other peptides in an operant conflict test. Regul Pept. 1992;41:61–69. [PubMed]
Heilig M, McLeod S, Brot M, Heinrichs SC, Menzaghi F, Koob GF, Britton KT. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology. 1993;8:357–363. [PubMed]
Karlsson RM, Choe JS, Cameron HA, Thorsell A, Crawley JN, Holmes A, Heilig M. The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice. Psychopharmacology (Berl) 2008;195:547–557. [PubMed]
Kask A, Kivastik T, Rago L, Harro J. Neuropeptide Y Y1 receptor antagonist BIBP3226 produces conditioned place aversion in rats. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23:705–711. [PubMed]
Kask A, Harro J, von Horsten S, Redrobe JP, Dumont Y, Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Biobehav Rev. 2002;26:259–283. [PubMed]
Kim M, Campeau S, Falls WA, Davis M. Infusion of the non-NMDA receptor antagonist CNQX into the amygdala blocks the expression of fear-potentiated startle. Behav Neural Biol. 1993;59:5–8. [PubMed]
Kokare DM, Dandekar MP, Chopde CT, Subhedar N. Interaction between neuropeptide Y and alpha-melanocyte stimulating hormone in amygdala regulates anxiety in rats. Brain Res. 2005;1043:107–114. [PubMed]
Kopp J, Xu ZQ, Zhang X, Pedrazzini T, Herzog H, Kresse A, Wong H, Walsh JH, Hokfelt T. Expression of the neuropeptide Y Y1 receptor in the CNS of rat and of wild-type and Y1 receptor knock-out mice. Focus on immunohistochemical localization. Neuroscience. 2002;111:443–532. [PubMed]
McDonald AJ, Pearson JC. Coexistence of GABA and peptide immunoreactivity in non-pyramidal neurons of the basolateral amygdala. Neurosci Lett. 1989;100:53–58. [PubMed]
Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev. 1998;50:143–150. [PubMed]
Morgan CA, 3rd, Wang S, Southwick SM, Rasmusson A, Hazlett G, Hauger RL, Charney DS. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol Psychiatry. 2000;47:902–909. [PubMed]
Nakajima M, Inui A, Teranishi A, Miura M, Hirosue Y, Okita M, Himori N, Baba S, Kasuga M. Effects of pancreatic polypeptide family peptides on feeding and learning behavior in mice. J Pharmacol Exp Ther. 1994;268:1010–1014. [PubMed]
Parker RM, Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci. 1999;11:1431–1448. [PubMed]
Primeaux SD, Wilson SP, Cusick MC, York DA, Wilson MA. Effects of altered amygdalar neuropeptide Y expression on anxiety-related behaviors. Neuropsychopharmacology. 2005;30:1589–1597. [PubMed]
Qian J, Colmers WF, Saggau P. Inhibition of synaptic transmission by neuropeptide Y in rat hippocampal area CA1: modulation of presynaptic Ca2+ entry. J Neurosci. 1997;17:8169–8177. [PubMed]
Rainnie DG, Asprodini EK, Shinnick-Gallagher P. Inhibitory transmission in the basolateral amygdala. J Neurophysiol. 1991;66:999–1009. [PubMed]
Redrobe JP, Dumont Y, Herzog H, Quirion R. Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice. Behav Brain Res. 2003;141:251–255. [PubMed]
Redrobe JP, Dumont Y, Herzog H, Quirion R. Characterization of neuropeptide Y, Y(2) receptor knockout mice in two animal models of learning and memory processing. J Mol Neurosci. 2004;22:159–166. [PubMed]
Sajdyk TJ, Vandergriff MG, Gehlert DR. Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur J Pharmacol. 1999;368:143–147. [PubMed]
Sajdyk TJ, Schober DA, Gehlert DR. Neuropeptide Y receptor subtypes in the basolateral nucleus of the amygdala modulate anxiogenic responses in rats. Neuropharmacology. 2002a;43:1165–1172. [PubMed]
Sajdyk TJ, Schober DA, Smiley DL, Gehlert DR. Neuropeptide Y-Y2 receptors mediate anxiety in the amygdala. Pharmacol Biochem Behav. 2002b;71:419–423. [PubMed]
Sajdyk TJ, Johnson PL, Leitermann RJ, Fitz SD, Dietrich A, Morin M, Gehlert DR, Urban JH, Shekhar A. Neuropeptide Y in the amygdala induces long-term resilience to stress-induced reductions in social responses but not hypothalamic-adrenal-pituitary axis activity or hyperthermia. J Neurosci. 2008;28:893–903. [PubMed]
Teppen TL, Urban JH. Regulation of Neuropeptide Y (NPY) Expression in the Amygdala and Hippocampus in a Rodent Model of Conditioned Fear. Society for Neuroscience (Abstract Viewer/Itinerary Planner. Washington D, ed); New Orleans. 2003.
Thorsell A, Heilig M. Diverse functions of neuropeptide Y revealed using genetically modified animals. Neuropeptides. 2002;36:182–193. [PubMed]
Thorsell A, Carlsson K, Ekman R, Heilig M. Behavioral and endocrine adaptation, and up-regulation of NPY expression in rat amygdala following repeated restraint stress. Neuroreport. 1999;10:3003–3007. [PubMed]
Thorsell A, Svensson P, Wiklund L, Sommer W, Ekman R, Heilig M. Suppressed neuropeptide Y (NPY) mRNA in rat amygdala following restraint stress. Regul Pept. 1998;75–76:247–254. [PubMed]
Thorsell A, Michalkiewicz M, Dumont Y, Quirion R, Caberlotto L, Rimondini R, Mathe AA, Heilig M. Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression. Proc Natl Acad Sci U S A. 2000;97:12852–12857. [PubMed]
Tschenett A, Singewald N, Carli M, Balducci C, Salchner P, Vezzani A, Herzog H, Sperk G. Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur J Neurosci. 2003;18:143–148. [PubMed]
Walker DL, Davis M. Double dissociation between the involvement of the bed nucleus of the stria terminalis and the central nucleus of the amygdala in startle increases produced by conditioned versus unconditioned fear. J Neurosci. 1997;17:9375–9383. [PubMed]
Walker DL, Paschall GY, Davis M. Glutamate receptor antagonist infusions into the basolateral and medial amygdala reveal differential contributions to olfactory vs. context fear conditioning and expression. Learn Mem. 2005;12:120–129. [PubMed]
Wieland HA, Engel W, Eberlein W, Rudolf K, Doods HN. Subtype selectivity of the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on feeding in rodents. Br J Pharmacol. 1998;125:549–555. [PubMed]
Wieland HA, Willim KD, Entzeroth M, Wienen W, Rudolf K, Eberlein W, Engel W, Doods HN. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226. J Pharmacol Exp Ther. 1995;275:143–149. [PubMed]
Wieronska JM, Smialowska M, Branski P, Gasparini F, Klodzinska A, Szewczyk B, Palucha A, Chojnacka-Wojcik E, Pilc A. In the amygdala anxiolytic action of mGlu5 receptors antagonist MPEP involves neuropeptide Y but not GABAA signaling. Neuropsychopharmacology. 2004;29:514–521. [PubMed]
Yehuda R, Brand S, Yang RK. Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. Biol Psychiatry. 2006;59:660–663. [PubMed]